Indication

Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Medicine details

Medicine name:
abrocitinib (Cibinqo)
SMC ID:
SMC2431
Pharmaceutical company
Pfizer Ltd
BNF chapter
Skin
Submission type
Full
Publication due date:
13 June 2022
SMC meeting date:
TBC
Patient group submission deadline:
04 April 2022